Our work reveals that the SOX9 transcription factor acts as a determinant of the ER− LSPC fate and its upregulation enabled by loss of BLBC tumor suppressors contributes to lineage plasticity and the progression of benign lesions to invasive tumors during BLBC oncogenesis. Here, SOX9 is linked to neoplasm.